The text starts here.

News Release

07/27/2017
U.S. FDA APPROVES ADDITIONAL USE OF ANTIEPILEPTIC DRUG FYCOMPA® AS MONOTHERAPY FOR PARTIAL-ONSET SEIZURES
07/25/2017
EISAI SUBMITS SIMULTANEOUS APPLICATIONS IN THE UNITED STATES AND EUROPE FOR LENVATINIB IN HEPATOCELLULAR CARCINOMA
06/05/2017
EISAI TO PRESENT RESULTS OF PHASE III TRIAL OF LENVIMA® (LENVATINIB) AS FIRST-LINE TREATMENT FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA IN ORAL SESSION AT 53RD ASCO ANNUAL MEETING
06/05/2017
EISAI TO PRESENT RESULTS OF PHASE Ib/II STUDY OF ANTICANCER AGENT LENVIMA® (LENVATINIB) IN COMBINATION WITH ANTI-PD-1 ANTIBODY PEMBROLIZUMAB FOR THE TREATMENT OF ENDOMETRIAL CARCINOMA AT 53RD ASCO ANN
06/01/2017
INITIATIVES FOR DEVELOPING NEW MEDICINES FOR NEGLECTED TROPICAL DISEASES AND MALARIA
04/19/2017
Eisai (China)’s Total 1.98 Million RMB Worth of Medicine Donation to "Health to Countryside" Activity for Four Consecutive Years
04/11/2017
SPEEDY CARE TO RELIEVE FATIGUE! EISAI TO LAUNCH "CHOCOLA BB® GOLD RICH"HIGHEST COMBINATION OF ACTIVE INGREDIENTS IN CHOCOLA BB SERIES. EASY TO DRINK BERGAMOT FLAVOR
04/05/2017
EISAI AND MEIJI ENTER INTO LICENSING AGREEMENT CONCERNING PARKINSON’S DISEASE DRUG SAFINAMIDE IN JAPAN AND ASIA
04/05/2017
EISAI PRESENTS DATA OF MECHANISMS OF ACTION RELATING TO TUMOR IMMUNE RESPONSE REGARDING COMBINATION OF ANTICANCER AGENT LENVATINIB WITH ANTI-PD-1 ANTIBODY AT AACR 108TH ANNUAL MEETING
03/28/2017
GERMAN FEDERAL JOINT COMMITTEE (G-BA) CONFIRMS ADDITIONAL BENEFIT OF ANTICANCER AGENT KISPLYX® (LENVATINIB MESYLATE) IN TREATMENT OF ADVANCED RENAL CELL CARCINOMA